Irritable Bowel Syndrome Treatment Market Development, Trends, Segmentations Ana

1. Title: Irritable Bowel Syndrome (IBS) Treatment Market Summery: Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M)], Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies) Description: The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The growth of the irritable bowel syndrome (IBS) treatment market is primarily attributed to the key driving factors such as increasing IBS diseases prevalence and rising research & development activities. However, the limited number of product availability and treatment inefficiency hinder the market growth. Ironwood Pharmaceuticals, Inc.; AbbVie.; Sebela Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Alfasigma S.p.A.; Astellas Pharma Inc.; AstraZeneca; Synthetic Biologics, Inc.; Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the market. Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00006814/ Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. According to updated Rome IV criteria, the reverse condition of IBS-M is described as a model of hard or irregular stools in more than 25% of bowel movements. The prevalence is higher in the geriatric population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period, Buy Now: https://www.theinsightpartners.com/buy/TIPRE00006814/ The report segments global irritable bowel syndrome (IBS) treatment market as Follows:

2. By Type    IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M) By Product      Rifaximin Eluxadoline Linaclotide Lubiprostone Others By Distribution Channel    Hospitals Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies By Geography  North America o  US  Canada  Mexico  Europe o  France  Germany  UK  Spain  Italy  Rest of Europe  Asia Pacific (APAC) o  China  India  Japan  Australia  South Korea

3.  Rest of APAC  Middle East and Africa (MEA) o  Saudi Arabia  UAE  South Africa  Rest of MEA  South and Central America (SCAM) o  Brazil  Argentina  Rest of SCAM Company Profiles           Ironwood Pharmaceuticals, Inc. AbbVie. Sebela Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited Alfasigma S.p.A. Astellas Pharma Inc. AstraZeneca Synthetic Biologics, Inc. Bausch + Lomb Incorporated Lannett Company Inc About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876